Leah Shifra Price, freelance biostatistician at freelance platform for scientists Kolabtree, discusses how a flexible workforce can speed up trials and remove delays in clinical trials.
CRISPR might have taken the world by storm but what’s next for gene editing technology? Ashley Jacobi, senior staff scientist at Integrated DNA Technologies (IDT) examines what's next.
Panna Sharma, CEO of clinical stage oncology biotech Lantern Pharma, speaks to EPM about how his company’s artificial intelligence platform could help revolutionise drug development and ultimately change the way we treat cancer.
Robert Sedlock, director of technical training and development for Natoli Engineering details a robust tablet formulation strategy from development to production.
Michael Avraam, head of solutions engineering at ChargePoint Technology explains how containment valves and wireless monitoring mitigate risk during HPAPI manufacture.
With emerging biotechs playing a critical part in developing new drugs, Merck attempts to understand the interactions between parties when manufacturing monoclonal antibodies (mAbs).
The pharmaceutical industry is one that has arguably created more breakthrough feats of human endeavour than any other, but is it missing an important new breakthrough closer to home?
